Bright Minds Biosciences Inc.
DRUG.CNCNQHealthcare● Active
$96.12
$-6.55(-6.38%)
Market Cap$746036822
P/E Ratio—
52W High$170
52W Low$33.01
Bright Minds Biosciences Inc. (DRUG.CN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DRUG.CN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 19, 2026EPS Actual
-$1.10
Est. -$1.20 · +8.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 19, 2026
After Market Close
▲ Beat EPS🔥 6-Quarter EPS Beat Streak
DRUG.CN reports quarterly as a CNQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$1.79 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 19, 2026 | -$1.20 | -$1.10 | +8.1% | — | — | — |
| ▲ Q1 FY2026 | Feb 19, 2026 | -$1.19 | -$0.98 | +17.8% | — | — | — |
| ▲ Q4 FY2025 | Dec 24, 2025 | -$0.78 | -$0.57 | +27.3% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.43 | -$0.42 | +3.3% | — | — | — |
| ▲ Q1 FY2025 | Feb 13, 2025 | -$0.60 | $0.01 | +101.3% | — | — | — |
| ▲ Q3 FY2024 | Sep 30, 2024 | -$0.60 | -$0.17 | +72.3% | — | — | — |
| — Q3 FY2024 | Aug 14, 2024 | — | $0.05 | — | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$1.79
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 19, 2026Beat
EPS Actual
-$1.10
EPS Est.
-$1.20
EPS Surpr.
+8.1%
Revenue
—
Q1 FY2026
Feb 19, 2026Beat
EPS Actual
-$0.98
EPS Est.
-$1.19
EPS Surpr.
+17.8%
Revenue
—
Q4 FY2025
Dec 24, 2025Beat
EPS Actual
-$0.57
EPS Est.
-$0.78
EPS Surpr.
+27.3%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.42
EPS Est.
-$0.43
EPS Surpr.
+3.3%
Revenue
—
Q1 FY2025
Feb 13, 2025Beat
EPS Actual
$0.01
EPS Est.
-$0.60
EPS Surpr.
+101.3%
Revenue
—
Q3 FY2024
Sep 30, 2024Beat
EPS Actual
-$0.17
EPS Est.
-$0.60
EPS Surpr.
+72.3%
Revenue
—
Q3 FY2024
Aug 14, 2024
EPS Actual
$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $-3.87 | $-3.87 | $-3.87 | 2 |
| Q2 FY2027 | $-3.39 | $-3.39 | $-3.39 | 2 |
| Q1 FY2027 | $-3.22 | $-3.22 | $-3.22 | 2 |
| Q4 FY2026 | $-2.81 | $-2.81 | $-2.81 | 4 |
| Q3 FY2026 | $-3.72 | $-2.45 | $-0.46 | 6 |
| Q2 FY2026 | $-2.72 | $-1.77 | $-0.82 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 19, 2026 | +8.1% | $102.39 | $103.73 | +1.31% |
| ▲ Q1 FY2026 | Feb 19, 2026 | +17.8% | $111.51 | $115.10 | +3.22% |
| ▲ Q4 FY2025 | Dec 24, 2025 | +27.3% | $115.56 | $118.00 | +2.11% |
| ▲ Q2 FY2025 | May 15, 2025 | +3.3% | $45.71 | $45.23 | -1.05% |
| ▲ Q1 FY2025 | Feb 13, 2025 | +101.3% | $65.21 | $66.76 | +2.38% |
| ▲ Q3 FY2024 | Sep 30, 2024 | +72.3% | $1.47 | $1.47 | +0.00% |
| — Q3 FY2024 | Aug 14, 2024 | — | $1.45 | $1.45 | +0.00% |
| — Q2 FY2024 | May 15, 2024 | — | $1.57 | $1.43 | -8.92% |
Q2 FY2026+1.31%
Report Date
May 19, 2026
EPS Beat/Miss
+8.1%
Price Before
$102.39
Price After
$103.73
Q1 FY2026+3.22%
Report Date
Feb 19, 2026
EPS Beat/Miss
+17.8%
Price Before
$111.51
Price After
$115.10
Q4 FY2025+2.11%
Report Date
Dec 24, 2025
EPS Beat/Miss
+27.3%
Price Before
$115.56
Price After
$118.00
Q2 FY2025-1.05%
Report Date
May 15, 2025
EPS Beat/Miss
+3.3%
Price Before
$45.71
Price After
$45.23
Q1 FY2025+2.38%
Report Date
Feb 13, 2025
EPS Beat/Miss
+101.3%
Price Before
$65.21
Price After
$66.76
Q3 FY2024+0.00%
Report Date
Sep 30, 2024
EPS Beat/Miss
+72.3%
Price Before
$1.47
Price After
$1.47
Q3 FY2024+0.00%
Report Date
Aug 14, 2024
EPS Beat/Miss
—
Price Before
$1.45
Price After
$1.45
Q2 FY2024-8.92%
Report Date
May 15, 2024
EPS Beat/Miss
—
Price Before
$1.57
Price After
$1.43
Avg Beat Reaction+1.33%
Beat Rate6 / 8 quarters
Largest Move-8.92% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DRUG.CN ends December
Bright Minds Biosciences Inc. (DRUG.CN) most recently reported earnings on May 19, 2026 for Q2 FY2026, posting EPS of $-1.10 — beating the analyst consensus of $-1.20 by +8.1%. DRUG.CN has beaten EPS estimates for 6 consecutive quarters. The next DRUG.CN earnings date is expected around September 1, 2026.
Each quarter, investors track DRUG.CN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DRUG.CN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DRUG.CN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DRUG.CN earnings · 5 questionsBright Minds Biosciences Inc.'s next earnings report is expected around September 1, 2026. DRUG.CN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DRUG.CN historically reports after market close (AMC).
DRUG.CN earnings datewhen is DRUG.CN earningsDRUG.CN next earnings datewhen does DRUG.CN report earningsDRUG.CN earnings calendar
▸ Source: FMP · Bright Minds Biosciences Inc. SEC filings · US GAAP · Bright Minds Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026